Search - tctmd.com

Displaying 1 - 1 of 1

Sort: Relevancy | Date

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Presentation TCT 2019

TCT 13: Alirocumab improve coronary plaque vulnerability: first randomized control trial to assess the effect of alirocumab for plaque vulnerabilityusing optical coherence tomography.

Presenter: yoichiro sugizaki

September 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.